XML 41 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenues:        
Revenue under collaborative research and development arrangements $ 16,475,083 $ 1,114,952 $ 25,055,890 $ 5,658,460
Revenue under collaborative research and development arrangements with affiliated entity 125,000 112,500 404,167 366,964
Grants and miscellaneous revenue 7,583,151 612,901 9,176,492 1,974,234
Total revenues 24,183,234 1,840,353 34,636,549 7,999,658
Operating expenses:        
Research and development 16,075,201 7,017,805 42,190,032 24,850,566
General and administrative 4,377,616 3,153,714 13,203,804 11,633,259
Gain on sale of assets 0 0 (1,000,000) 0
Total operating expenses 20,452,817 10,171,519 54,393,836 36,483,825
Income (Loss) from operations 3,730,417 (8,331,166) (19,757,287) (28,484,167)
Other income (expense):        
Interest and other income, net 214,982 97,174 499,590 218,249
Change in fair value of common stock warrants 518,877 (113,980) 467,877 204,484
Gain (loss) on investment in affiliated entity (659,054) 1,168,911 5,849,782 (666,212)
Net income (loss) before income tax benefit 3,805,222 (7,179,061) (12,940,038) (28,727,646)
Income tax benefit 1,789,246 0 1,789,246 0
Net income (loss) 5,594,468 (7,179,061) (11,150,792) (28,727,646)
Net (income) loss attributable to non-controlling interest 0 1,486 (84,769) 17,337
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. $ 5,594,468 $ (7,177,575) $ (11,235,561) $ (28,710,309)
Net income (loss) per common share attributable to Inovio Pharmaceuticals, Inc. stockholders:        
Basic (in USD per share) $ 0.08 $ (0.12) $ (0.17) $ (0.49)
Diluted (in USD per share) $ 0.07 $ (0.12) $ (0.18) $ (0.52)
Weighted average number of common shares outstanding used in per share calculations:        
Basic (in shares) 72,029,644 60,392,911 66,846,481 58,625,740
Diluted (in shares) 73,961,237 60,602,831 67,018,961 58,936,414